1Whiting D R,Guariguata L,Weil C,et al.IDF diabetes atlas:global estimates of the prevalence of diabetes for 2011and 2030[J].Diabetes Res Clin Pract,2011,94(3):311.
2Kahn S E,Cooper M E,Del Prato S.Pathophysiology and treatment of type 2 diabetes:perspectives on the past,present,and future[J].The Lancet,2014,383(9922):1068.
3Buse J B,Bergenstal R M,Glass L C,et al.Use of twicedaily exenatide in basal insulin-treated patients with type 2diabetes:a randomized,controlled trial[J].Ann Intern Med,2011,154(2):103.
4American Diabetes Association.Standards of medical care in diabetes-2010[J].Diabetes care,2010,33(S1):S11.
5Emerging Risk Factors Collaboration,Sarwar N,Gao P,et al.Diabetes mellitus,fasting blood glucose concentration,and risk of vascular disease:a collaborative meta-analysis of 102prospective studies[J].Lancet,2010,375(9733):2215.
6Koshiba K,Nomura M,Nakaya Y,et al.Efficacy of glimepiride on insulin resistance,adipocytokines,and atherosclerosis[J].J Med Invest,2006,53(1/2):87.
7Seino S,Shibasaki T,Minami K.Dynamics of insulin secretion and the clinical implications for obesity and diabetes[J].J Clin Invest,2011,121(6):2118.
8Silva MA,Cau SB,Lopes RA,et al.Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2diabetes mellitus[J].Clin Sci(Lond),2015,129(7):533-545.
9Talebpour M,Talebpour A,Barzin G,et al.Effects of laparoscopic gastric plication(LGP)in patients with type 2 diabetes,one year follow-up[J].J Diabetes Metab Disord,2015,14:60.
10Mosley JF 2nd,Smith L,Everton E,et al.Sodium-Glucose Linked Transporter 2(SGLT2)Inhibitors in the Management of Type-2Diabetes:A Drug Class Overview[J].P T,2015,40(7):451-462.
